Acute Coronavirus 2 Syndrome (SARS-Cov-2)

Shastzmiller S

Published on: 2020-06-30

Abstract

Keywords

COVID-19; SARS-COV; Remdesivir

Introduction

Coronaviruses are a large family of viruses that can cause disease in animals or humans. COVID-19 a name given to the infectious disease caused by the newly unveiled, newly acquired coronavirus virus, known as acute coronavirus 2 syndrome (SARS-CoV-2). This new virus and disease was unknown before the outbreak began in Wuhan, China, in December 2019. Not everyone infected with SARS-CoV-2 will eventually contract the disease, COVID-19, and people can suffer from anything else with no symptoms of being sick Mildly or severely ill [1]. The COVID 19 world pandemic outbreak in China and its fast spreading due to the intense Air travel worldwide, the deadly viruses spread to all countries continents through air travel routes [2,3]. Severe acute respiratory syndrome – associated coronavirus (SARS-COV) was introduced to the United States through air travel. Although several studies have addressed the risk of SARS-COV transmission within aircraft cabins, the magnitude of the risk remains [4]. The distinguished professors who compare the corona to the flu: the state of the flu is preferable (Figure 1).

Figure 1: The fast spread of COVID -19 by air travel all over the earth.

There is a remedy, a medicine (Tamiflu) and there is a vaccine. However, every year, masses of people die from the flu. Because mostly not vaccinated. Corona has currently no cure (testing the anti-Ebola candidate Remdesivir) Conducting experiments towards a vaccine and the virus mutates and spreads and migrates through the sewage and fecal system. Don't panic. Just be aware and follow the instructions and most importantly. Do not under-estimate it [5-7]. Because the drug failed in Ebola trials, it is too early to say whether it will work in COVID-19 patients. However, some scientists agree that remdesivir is the most promising candidate to date and examines preclinical data where Remdesivir can clear two other infections by fatal coronaviruses, SARS and MERS. Over a number of preclinical data are the real data that showed the full recovery of the first American patient, a 35-year-old man in Washington after taking medication. Although this requires celebration, the actual clinical data confirming the role of remdesivir in recovery is yet to come [8,9]. Lethal mutagenesis is beyond the direction of virus extinction mediated by enhanced mutation rates during viral genome replication, and is currently being investigated as a new antiviral potential strategy [10]. Viral load and virus capacity are known to affect the extinction of the virus. Here we examine the effect or multiplicity of infection (MOI) on the progeny production of some RNA viruses under enhanced mutagenesis. The effect of a basic 5-fluorouracil (FU) mutation on replication of the urinary tract infection (LCMV) can also inhibit the production of the powder and the extinction of the virus in infections with high multiplicity of infection (MOI) or moderate titration without extinction in MOI. The effect of MOI is similar to the vascular LCMV and vascular virus (VSV), but minimal or absent for oral and abdominal disease (FMDV) and meningitis (EMCV).The increase in Shannon mutation frequency and entropy (mutant spectrum complexity) as a result of virus transfer in the presence of FU, was more pronounced in low MOI for LCMV and VSV, and high MOI for FMDV and EMCV [11]. We present an extension of the deadly defection model that agrees with the experimental results. Health officials from WHO have noted that Gilead's Remdesivir has demonstrated efficacy in treating the coronavirus infection. Remdesivir is a broad-spectrum antiviral drug originally designed to target Ebola. Researchers have found that Remdesivir is highly effective at fighting the novel coronavirus. This treatment is not yet approved in humans, but two clinical trials for this drug have been implemented in China. One clinical trial was recently also approved by the FDA in the United States. Gilead Sciences has partnered with Chinese health authorities to conduct a randomized Phase III clinical trial to evaluate the use of the antiviral drug candidate study (GS-5734) for the potential treatment of corona virus. U.S. regulators on Friday 1 May 2020, approved emergency use of an experimental drug, which appears to help Coronavirus patients recover faster. It is the first drug presented to help fight COVID-19, which has killed more than 230,000 people worldwide [12]. The Food and Drug Administration took action after preliminary results of a government-sponsored study showed that Gilad's scientific research reduced recovery time by 31%, or about four days, for COVID-19 patients admitted. Read more: Remdesivir presents promising results as treatment for coronavirus, according to pharmaceutical manufacturer Gilad The study of 1,063 patients is the largest and most rigorous study of the drug and included a comparison group that received regular treatment just so that the effects of remdesivir can be rigorously assessed. President Donald Trump announced FDA action in the White House. Those who received the drug managed to leave the hospital within an average of 11 days compared to 15 days for the comparison group. The drug may reduce deaths, though it is uncertain of the partial results revealed so far (Figure 2).

Figure 2: The Synthesis of Remdesivir (credit ref. [³] [[i]]).

The National Institutes of Health, Dr. Anthony Pauchi, said the drug will become a new standard of care for COVID-19 patients as difficult as those in this study. The drug has not been tested in people with a milder illness and is currently being given IV IV in a hospital.

International Journal of Case Reports and Clinical Images

Acute Coronavirus 2 Syndrome (SARS-Cov-2)

Abstract

Keywords

Introduction

References